CEO AND CFO PROVIDE GROUNDBREAKING AI ANIMATED EARNINGS UPDATE IN INTERVIEW WITH A.A. MILNE’S WINNIE THE POOH, AND TENTPOLE CHARACTERSOVERALL REVENUE INCREASED YEAR-OVER-YEAR 21% IN 2025 TO $39.4 MILLION PRODUCTION SERVICES REVENUE INCREASED 50% YEAR-OVER-YEAR TO $26.8 MILLION KARTOON CHANNEL WATCH TIME SURGES 85% YEAR-OVER-YEAR, AMIDST RECORD SUBSCRIBERS AND BREAKOUT ENGAGEMENT ACROSS SVOD AND FAST PLATFORMS, AS GLOBAL DIGITAL DISTRIBUTION ECOSYSTEM SCALES KARTOON CHANNEL CONTINUES TO LEAD ALL COMPETITORS IN APPLE APP STORE VIEWER RATINGSOPERATING LOSS IMPROVES 24%; COMPANY TRANSITIONS TO HIGH-MARGIN FRANCHISE MONETIZATION IP-DRIVEN BUSINESS MODEL-NOT DEPENDENT ON ENERGY INPUT COSTS-POSITIONS COMPANY FOR RESILIENT, SCALABLE GROWTH IN A RISING COST ENVIRONMENT BEVERLY HILLS, Calif., March 31, 2026 (GLOBE NEWSWIRE) — Kartoon...

Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Cadrenal’s near-term development priority; broader 12-LOX platform remains a longer-term opportunity PONTE VEDRA, Fla., March 31, 2026 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update highlighting recent progress across its CAD-1005 program for HIT and broader 12-LOX inhibitor platform. The update reflects continued progress for CAD-1005, Cadrenal’s first-in-class 12-LOX inhibitor for suspected heparin-induced thrombocytopenia (HIT), including completion of its End-of-Phase...

Completed Business Combination and Began Trading on NYSE American Under Ticker Symbol “AIB” on March 17, 2026 Existing 40MW Operating Data Center Provides Revenue-Generating Base as Company Advances Growth Plan Over $500 Million in Potential Contract Value Pending Execution of Definitive Agreements Company to Host First Virtual Webinar in April 2026 to Discuss Financial Results and Growth Strategy NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) — BlockchAIn Digital Infrastructure, Inc. (NYSE American: AIB) (“BlockchAIn” or the “Company”), a developer and operator of digital infrastructure focused on artificial intelligence (“AI”) and high-performance computing (“HPC”) workloads, today reported financial results for the fiscal year ended December 31, 2025, and highlighted recent commercial and strategic developments. On March 16, 2026,...

Revenue Growth of 26% year-over-year Defence Equipment revenues more than 2x from 2024 Total Assets of C$92M+, up ~60% year-over-year Europe & UK revenue grew 150%, driven by NATO-aligned defence business Current cash balance of ~C$41M Secured a NATO defence contract valued at up to C$9M in Dec 2025 Establishment of the Volatus Innovation & Drone Manufacturing Facility in Mirabel, QCMONTREAL, March 31, 2026 (GLOBE NEWSWIRE) — Volatus Aerospace Inc. (TSX: FLT) (OTCQX: TAKOF) (Frankfurt: ABB.F) (“Volatus” or the “Company”), a Canadian-controlled global aerospace and defence company delivering integrated uncrewed systems, aerial intelligence, and mission-critical operational services, today released its audited consolidated financial results for the fiscal year ended December 31, 2025. Fiscal 2025 was the Company’s first...

– Revenue of $7.3 million, 22% growth – Gross margin of 35% – Adjusted EBITDA margin of 10% HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) — KOIL Energy Solutions, Inc. (OTCQB: KLNG), a specialist in deepwater energy production and distribution equipment and services, released today its fourth quarter and full year 2025 results. “We achieved a record revenue of $7.3 million this quarter,” said Erik Wiik, President and Chief Executive Officer of KOIL Energy. “Our growth initiatives are delivering profitable growth with an EBITDA margin of 10% while we continue to invest heavily in growth.” Fourth Quarter 2025 Results: For the three months ending December 31, 2025, KOIL Energy generated revenues of $7.3 million dollars. This is 22% higher than Q4 last year and 14% higher than last quarter. Both...

HOLMDEL, N.J., March 31, 2026 (GLOBE NEWSWIRE) — BIO-key® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, announced its fourth quarter (Q4’25) and year ended December 31, 2025 (2025) results. BIO-key will host an investor call today at 10:00am ET (details below). Highlights:  •   2025 Revenue:   $6.1M  •   2026 Outlook:   Solid revenue growth + improved bottom line  •   Preliminary Q1’26 Revenue:   $2.2M, up 37% vs. Q1’25 and 80% vs. Q4’25  •   2025 Cash Position:   $2.7M, up $2.3M vs. $0.4M vs. 2024BIO-key CEO, Mike DePasquale commented, “We had a broad base of achievements in 2025, the revenue and bottom-line benefits of which will be realized in early 2026 and beyond. In 2025, we completed our strategic transition to selling...

NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “We are at an important juncture for the belapectin development program. During 2025, we made meaningful progress advancing the belapectin program and continuing our analysis of the NAVIGATE dataset in patients with MASH cirrhosis and portal hypertension. We are encouraged by the signals observed, including additional biomarkers from the NAVIGATE dataset, and remain focused on evaluating the data as we engage with regulators, potential partners, and leading experts to determine the optimal...

Completed End-of-Phase 2 meeting with the FDA; Company expects to provide a regulatory update in early 2Q 2026 and remains on track to initiate a Phase 3 study in chronic tetraplegia in mid-2026. Company expects to present clinical data from independent, blinded biomechanical gait analyses of the CONNECT SCI study in 2Q 2026, providing additional evidence with the potential to further support the systemic biological effect of NVG-291, differentiating genuine neural recovery from compensatory movement. Company expects to expand NVG-291 into complementary clinical indications, as informed by established preclinical efficacy, with prioritization expected to be announced by mid-2026. Successful Nasdaq listing and continued growth of leadership team supports the Company’s emergence as a leader in the development of neuroreparative therapeutics.VANCOUVER,...

FY 2025 net product revenues increased 65% to $1,005,000 Current shelf capacity exhausted after raise of $4 million through an ATM facilityWASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, reported today its financial results for the 2025 fiscal year ended December 31, 2025. Financial Highlights for the Fiscal Year Ended December 31, 2025:Net product revenues increased 65% from $607.6 thousand in 2024 to $1.0 million in 2025, driven by rising sales, price increases, and fewer returns. The Company achieved a gross profit of approximately $223.8 thousand in 2025, compared with approximately $222.8 thousand in 2024. Gross profit remained relatively stable despite inventory write-offs...

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, March 31, 2026 (GLOBE NEWSWIRE) — ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces its financial and operating results for the full year 2025:Commercial traction: The Company initiated the commercialization of its first technology platform and sold 117 ARC-EX® Systems, demonstrating strong commercial traction for its groundbreaking external spinal stimulation system. ARC-EX was sold to more than 80 US rehabilitation clinics by the end of the year. Regulatory milestones: The...